Immunity in the balance: Fatal disseminated adenovirus infection in a patient undergoing plasma exchange and immunosuppressive chemotherapy for anti-glomerular basement membrane disease.
Jeremy W JacobsCristina A Figueroa VillalbaKristin StendahlChristopher A TormeyElizabeth A AbelsPublished in: Journal of clinical apheresis (2023)
Anti-glomerular basement membrane (anti-GBM) disease (formerly known as Goodpasture's syndrome) is a rare autoinflammatory condition that affects the renal and/or pulmonary capillaries. The standard therapeutic regimen for anti-GBM disease involves therapeutic plasma exchange (TPE), cyclophosphamide, and corticosteroids to rapidly remove and inhibit autoantibody production and reduce organ inflammation. Herein we report an 82-year-old female who developed anti-GBM disease but expired despite therapy, secondary to multi-organ failure in the setting of disseminated adenovirus disease. We discuss the utility and potential adverse effect of daily TPE for a protracted course (ie, 10-14 days), the recommended TPE intensity in the 2023 American Society for Apheresis guidelines, updated from every-other-day TPE in the 2019 guidelines, despite no new data. We also highlight the potential for unusual infections to occur in these patients due to the profound immunosuppression, and discuss the importance of balancing immunosuppression to treat the disease with close surveillance of any potential opportunistic infections.
Keyphrases
- oxidative stress
- public health
- stem cells
- low dose
- emergency department
- case report
- end stage renal disease
- machine learning
- squamous cell carcinoma
- clinical practice
- risk assessment
- ejection fraction
- prognostic factors
- high dose
- human health
- bone marrow
- big data
- artificial intelligence
- intellectual disability
- cell therapy